TriSalus Life Sciences, Inc. (TLSI) income statement
TLSINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as TLSIW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$2.17−0.28 (-11.22%)
Close on Nov 19, 2026Market cap $133.93MP/E –Yield –
TriSalus Life Sciences, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 85.8%
- Operating margin
- -67.7%
- Net margin
- -62.6%
- Return on equity, FY2025
- 131.3%
Financial strength
- Current ratio
- 5.35
- Debt to equity
- 5.05
- Debt to assets
- 52.9%
- Cash to current liabilities
- 414.3%
Valuation
- P/E ratio
- –
- Price to sales
- 2.97
- Price to book
- 20.45
- Dividend yield
- –
See a number that looks wrong?